Merck has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for ISENTRESS, a 600 mg. tablet coated in film and paired with other anti-retroviral prescriptions for those who have been diagnosed HIV-1. Read More »
The FDA says it is willing to look into and evaluate a drug that could help treat children who suffer from seizures. Read More »
Hematogenix Laboratory Services, a company that provides integrated pathology services for drug development, recently announced that that Merck & Co. Inc. has included it as one of the national reference laboratories for U.S. Food and Drug Administration (FDA)-approved PD-L1 companion diagnostic assay PD-L1 IHC 22C3 pharmDx for Keytruda. Read More »
Otsuka Pharmaceutical has entered into a licensing agreement that gives it exclusive rights to develop and commercialize Teva Pharmaceutical Industries' migraine prevention drug fremanezumab in Japan. Read More »
Allergan PLC, a global biopharmaceutical company, recently concluded its $2.9 billion acquisition of LifeCell Corp., a business that develops regenerative medicine. Read More »
Janssen Research & Development LLC has identified new partnerships through the company’s Janssen Human Microbiome Institute, a program that develops microbial products through innovation and discovery. Read More »
AM-Pharma B.V. has finished recruiting for its Phase II trial of treatment for individuals with Acute Kidney Injury. Read More »
Puma Biologics reports the U.S. Food and Drug Administration has posted the documents that were used for briefing at the Oncologic Drugs Advisory Committee (ODAC) May 24. Read More »
TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha. Read More »
DrFirst, an electronic prescribing company, has acquired VisibilityRx, a provider of clinical trial recruitment services to life sciences, clinical research organizations and pharmacies. Read More »
Personal Genome Diagnostics Inc. has received a National Cancer Institute contract to develop a novel diagnostic for helping identify patients who are most likely to benefit from cancer drugs called checkpoint inhibitors. Read More »
Mylan N.V. recently released a statement in response to a Financial Times article entitled “HIV/Aids drug for developing world face threat of disruption.” Read More »
Abbott recently announced that its molecular test, the Abbott RealTime Zika Test, has been authorized by the U.S. Food and Drug Administration (FDA). Read More »
A new Glaukos Corporation study reveals that the cost of two iStent Trabecular Micro-Bypass Stents could cost lower cumulatively in five years compared to others like the selective laster trabeculoplasty (also known as the SLT) or topical glaucoma medication. Read More »
CVS Health recently announced that it will sponsor the American Heart Association’s Go Red For Women movement and pledge to raise $10 million over the next three years to support research efforts. Read More »
NovellusDx has been given a new patent by the name of "Methods and Systems for Identifying Patient Specific Driver Mutations." Read More »
The U.S. Food and Drug Administration (FDA) has permitted the use of subcutaneous Actemra (tocilizumab) to assist adults who are receiving treatment for giant cell arteritis. Read More »
EMED Technologies Corp.'s SCIg60 Infusion System is the first Immune Globulin Subcutaneous (Human) mechanical pump infusion system to be approved by the U.S. Food and Drug Administration. Read More »
A recent publication by Lancet HIV found a link between the criminalization of drugs and the spread of HIV. Read More »
The U.S. Food and Drug Administration has given Bayer a priority review for its New Drug Application for copanlisib, a drug to be used for relapses of refractory follicular lymphoma in individuals who have had a minimum of two therapies. Read More »
Alerts Sign-up
